Welcome to our dedicated page for aiki news (Ticker: aiki), a resource for investors and traders seeking the latest updates and insights on aiki stock.
AIkido Pharma Inc., established in 1967, is a biotechnology company focusing on developing small-molecule anti-cancer therapeutics. The company leverages patented technology from leading universities and esteemed researchers to create an innovative drug platform. AIkido Pharma has forged significant partnerships with renowned institutions such as The University of Texas at Austin and Wake Forest University. The company's diverse pipeline includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Besides oncology, AIkido Pharma is expanding its portfolio to address unmet medical needs, including developing a broad-spectrum antiviral platform targeting viruses like Influenza, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus.
In recent news, AIkido Pharma has been active with its $2 million share repurchase program, showcasing commitment to shareholder value. The company also highlights its collaborations and achievements in the broader biotechnology landscape, aiming to bring groundbreaking treatments to market. Investors and stakeholders can follow the latest updates and developments as AIkido Pharma continues to enhance its therapeutic offerings and strengthen its market presence.
Dominari Holdings Inc. (Nasdaq: DOMH) appointed George Way as Chief Financial Officer effective
DatChat has announced the launch of Habytat, a photorealistic metaverse featuring AI-powered pets. These virtual pets will mimic real-life interaction, growing from puppies and kittens to adults as users care for them. Users will be able to select from four dog breeds and two cat breeds for the initial launch in Spring 2023. The platform enhances user engagement through tasks such as feeding, training, and cleaning their pets. The initiative aims to democratize access to the metaverse and create a fun, interactive environment for pet lovers. For participation in breed selection, visit Habytat.io/pets.
Habytat, a metaverse platform by SmarterVerse Inc., a subsidiary of DatChat (NASDAQ: DATS), is launching early this spring, offering 200 artists complimentary virtual gallery spaces. This initiative aims to empower artists in showcasing and selling their work globally. The galleries will include technical support for digitizing physical art and integrating online sales, enhancing artists' online presence. Located in Habytat's Geniuz City, designed like Miami's Wynwood arts district, these galleries promote creativity and accessibility. Interested artists can apply through Habytat's website.
DatChat (NASDAQ: DATS) has appointed Wachsman as the agency of record for its subsidiary, Habytat by SmarterVerse, aimed at enhancing user engagement in the metaverse. CEO Darin Myman emphasized the goal of making metaverse technology accessible to a broader audience. Wachsman is recognized for its expertise in promoting innovative technologies and has received accolades from various industry publications. DatChat focuses on secure messaging and user privacy, providing a private social network that allows users control over their messages.
Dominari Holdings Inc. (Nasdaq: DOMH) has initiated a $2 million share repurchase program, with the first purchase of 4,000 shares at $3.1012 each completed on December 27, 2022. CEO Anthony Hayes emphasized that the stock is undervalued, aiming to enhance shareholder value through this program. The company plans to continue repurchasing shares based on market conditions and regulations. Dominari, transitioning to fintech, operates under its subsidiary, Dominari Financial Inc., while still developing its therapeutic portfolio through Aikido Labs, LLC.
AIkido Pharma Inc. has officially changed its name to Dominari Holdings Inc. and its ticker symbol from AIKI to DOMH, effective December 22, 2022. This decision was made during a board meeting on December 5, 2022. The rebranding aligns with the company's strategic shift from healthcare to financial services. Dominari is in the process of acquiring a registered broker-dealer and has allocated approximately $3.2 million towards this new subsidiary, Dominari Financial Inc., while also continuing to develop its existing therapeutic technology through AIkido Labs.
FAQ
What is the market cap of aiki (aiki)?
What is AIkido Pharma Inc.'s primary focus?
What recent achievements has AIkido Pharma Inc. accomplished?
Who are AIkido Pharma Inc.'s key partners?
What types of cancer therapies does AIkido Pharma Inc. develop?
Is AIkido Pharma Inc. involved in antiviral research?
How does AIkido Pharma Inc. contribute to oncology research?
What is the company's approach to enhancing shareholder value?
How does AIkido Pharma Inc. utilize its partnerships?
What makes AIkido Pharma Inc.'s antiviral platform unique?